CervoMed Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
CervoMed Inc. (CRVO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $100.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-08-08
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-06-30 was $100.00K, a 66.67% decline year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $100.00K, a 50.00% decline year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-12-31 was $100.00K, a 50.00% decline year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-09-30 was $400.00K, a 33.33% increase year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $800.00K, a 0.00% change from fiscal 2021.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $800.00K, a 14.29% increase from fiscal 2020.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $700.00K, a 16.67% increase from fiscal 2019.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $600.00K, a 50.00% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-08 | $200.00K 10-Q · filed 2023-08-08 | $300.00K derived: sum of 3 quarters · filed 2023-08-08 | $700.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-15 | $200.00K derived: sum of 2 quarters · filed 2023-05-15 | $600.00K derived: sum of 3 quarters · filed 2023-05-15 | $900.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $500.00K derived: sum of 2 quarters · filed 2023-03-24 | $800.00K derived: sum of 3 quarters · filed 2023-08-08 | $800.00K 10-K · filed 2023-03-24 | |
| 2022-09-30 | $400.00K 10-Q · filed 2022-11-14 | $700.00K derived: sum of 2 quarters · filed 2023-08-08 | $700.00K 10-Q · filed 2022-11-14 | $1.10M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-08 | $500.00K 10-Q · filed 2023-08-08 | $700.00K derived: sum of 3 quarters · filed 2023-08-08 | $1.00M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-15 | $300.00K 10-Q · filed 2022-05-12 | $400.00K derived: sum of 2 quarters · filed 2023-05-15 | $700.00K derived: sum of 3 quarters · filed 2023-05-15 | $800.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $500.00K derived: sum of 2 quarters · filed 2023-03-24 | $600.00K derived: sum of 3 quarters · filed 2023-03-24 | $800.00K 10-K · filed 2023-03-24 | |
| 2021-09-30 | $300.00K 10-Q · filed 2022-11-14 | $400.00K derived: sum of 2 quarters · filed 2022-11-14 | $600.00K 10-Q · filed 2022-11-14 | $700.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-12 | $300.00K 10-Q · filed 2022-08-12 | $400.00K derived: sum of 3 quarters · filed 2022-08-12 | $700.00K derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-12 | $300.00K derived: sum of 2 quarters · filed 2022-05-12 | $600.00K derived: sum of 3 quarters · filed 2022-05-12 | $700.00K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $400.00K derived: sum of 2 quarters · filed 2022-03-18 | $500.00K derived: sum of 3 quarters · filed 2022-03-18 | $700.00K 10-K · filed 2022-03-18 | |
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-10 | $400.00K derived: sum of 2 quarters · filed 2021-11-10 | $600.00K 10-Q · filed 2021-11-10 | $700.00K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-11 | $300.00K 10-Q · filed 2021-08-11 | $400.00K derived: sum of 3 quarters · filed 2021-08-11 | $600.00K derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-07 | $300.00K derived: sum of 2 quarters · filed 2021-05-07 | $500.00K derived: sum of 3 quarters · filed 2021-05-07 | ||
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $300.00K derived: sum of 2 quarters · filed 2021-03-17 | $600.00K 10-K · filed 2021-03-17 | ||
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-12 | $500.00K 10-Q · filed 2020-11-12 | |||
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | $1.20M 10-K · filed 2020-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |